Biosyent Inc. (RX : TSX-V)
Common Stock
$14.44
CAD
-0.06 (-0.41%)
Last updated: 2026-07-02
RX
Biosyent Inc.
WealthAwesomePerformance
1 Day
-0.41%
1 Week
+3.66%
1 Month
+4.41%
YTD
+13.17%
Key Statistics
Market Cap
$163.63M
52W High
$15.73
52W Low
$10.52
P/E Ratio
18.51
50 Day MA
$14.22
200 Day MA
$13.28
Beta
0.63
Dividend Yield
1.41%
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/2/2026 | $14.64 | $14.64 | $14.44 | $14.44 | $14.44 | 2,573 |
| 6/30/2026 | $14.60 | $14.70 | $14.45 | $14.50 | $14.50 | 7,463 |
| 6/29/2026 | $14.42 | $14.69 | $14.25 | $14.69 | $14.69 | 5,545 |
| 6/26/2026 | $13.92 | $14.30 | $13.92 | $14.05 | $14.05 | 22,577 |
| 6/25/2026 | $14.01 | $14.09 | $13.90 | $13.93 | $13.93 | 15,394 |
| 6/24/2026 | $14.01 | $14.15 | $13.94 | $14.00 | $14.00 | 9,852 |
| 6/23/2026 | $14.06 | $14.08 | $13.85 | $14.04 | $14.04 | 26,188 |
| 6/22/2026 | $14.00 | $14.00 | $13.98 | $14.00 | $14.00 | 26,765 |
| 6/19/2026 | $14.02 | $14.02 | $13.95 | $13.95 | $13.95 | 10,602 |
| 6/18/2026 | $13.85 | $14.05 | $13.85 | $13.95 | $13.95 | 87,690 |
Analyst Price Targets
Based on analyst covering RX
Wall Street analysts forecast RX stock price to rise 24.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$18.00
+24.7% Upside
Current Price
C$14.44
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RX's historical volatility
30-Day Vol
19.9%
Annualized
90-Day Vol
26.1%
Annualized
Trend (90d)
-4.6%
Annualized drift
90d Mean
C$14.20
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$14.36 | C$13.41 โ C$15.38 |
| 60 trading days | C$14.28 | C$12.96 โ C$15.74 |
| 90 trading days | C$14.20 | C$12.61 โ C$16.00 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Financials
- Revenue (TTM)
- $45.98M
- EBITDA
- $12.55M
- Profit Margin
- 19.65%
- ROE (TTM)
- 22.31%
- EPS (Diluted)
- 0.78
- Book Value
- 3.94
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
๐ฐ Recent Dividends
$0.0550
Ex: May 29, 2026
$0.0550
Ex: Feb 27, 2026
$0.0450
Ex: Nov 29, 2024
$0.0450
Ex: Sep 4, 2024
$0.0450
Ex: May 31, 2024
$0.0450
Ex: Feb 28, 2024
$0.0400
Ex: Nov 29, 2023
$0.0400
Ex: Aug 30, 2023
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE Report